Review Papers Claim by Claim

Visual review: "MERTK Inhibition as a Targeted Novel Cancer Therapy"

1. Mechanism — MERTK drives efferocytosis and anti‑inflammatory programs: Human iPSC- and PBMC-derived macrophages require MERTK kinase activity for high-efficiency apoptotic-cell uptake; Mertk-KD/KO mice phenocopy efferocytosis defects. This explains how tumor-associated MERTK enables immunosuppressive TAM phenotypes that blunt anti-tumor immunity (MERTK kinase requirement).
2. Tumor cell–intrinsic role — therapy resistance: MERTK signaling in NSCLC cell lines mediates resistance to irreversible EGFR TKIs; combined MERTK inhibitor (MRX‑2843) plus EGFR TKI restored sensitivity in vitro and xenografts, supporting combination strategies in subsets of tumors (MRX-2843 NSCLC results).
3. Tumor-specific MERTK dependency — pediatric brain tumors: Systems pharmacology screens pinpointed Mertk as a top dependency in ZFTA-RELA fusion-driven supratentorial ependymomas and pharmacologic inhibition reduced tumor growth in vivo, highlighting tumor-type selection as crucial (MERTK in ependymoma screening).
4. Reviews — therapeutic rationale and caveats: Multiple reviews synthesize TAM biology in cancer, concluding TAM inhibition could (1) block pro‑tumor signaling (AXL/MERTK) in cancer cells, (2) reduce efferocytosis-mediated immune suppression, and (3) synergize with checkpoint blockade or chemotherapy — but emphasize publication bias, model heterogeneity, and safety concerns (autoimmunity, impaired tissue repair) as major translational risks (Efferocytosis & cancer review).

• Species & model differences: Many functional results depend on mouse genetics or in vitro human iPSC-derived cells; tissue-resident macrophage phenotypes differ substantially across organs and species — a major translational blindspot (MerTK tissue-specific functions).
• Context dependence: In some fibrotic or chronic inflammatory contexts, elevated MERTK correlated with profibrotic programs (pulmonary fibrosis studies), suggesting inhibition might be beneficial there — but organ-specific consequences differ and could be harmful elsewhere (MERTK in pulmonary fibrosis).
• Safety unknowns: MERTK is essential in retina (RPE phagocytosis), heart macrophage–mitochondrial clearance, and organ homeostasis; inhibitors risk off-target functional deficits (vision, tissue repair) if systemic or chronic (MERTK in RPE and vision, MerTK role in cardiac macrophage mitophagy).

1. Biomarker-driven trials: prospectively measure tumor MERTK/GAS6, sMer, TAM macrophage signatures, and immune-infiltrate phenotypes to select tumor types and timing (e.g., post‑chemo cell death window) where inhibition could unmask anti‑tumor immunity (Biomarker need in TAM therapy).
2. Combination strategies: test MERTK inhibitors with ICIs or targeted inhibitors only in biomarker-positive tumors and use short-course peri‑treatment dosing to avoid chronic blockade of homeostatic efferocytosis (limit organ toxicities).
3. Organ-safety panels: include retinal function, cardiac mitochondrial assays, and wound healing readouts in IND-enabling GLP studies given noncancer roles of MERTK (RPE dependence on MERTK).
4. Cell-type selective delivery: pursue tumor‑directed delivery (antibody-drug conjugates, nanoparticle-encapsulated TKIs, or CAR‑macrophage strategies that reprogram MerTK pathways selectively) to limit systemic toxicities (CAR macrophage review).

• Robust randomized clinical trials across biomarker‑selected cohorts showing no improvement (or harm) in survival or durable responses when adding MERTK inhibition to established therapies (chemo, targeted, ICI) would falsify the claim that MERTK inhibition is a translatable cancer therapy.
• Preclinical evidence that chronic or intermittent MERTK blockade in humans causes unacceptable organ toxicity (retinal degeneration, impaired cardiac repair) that outweighs anti‑tumor benefit would similarly invalidate broad clinical use.

1. Windowed MERTK inhibition + ICI in syngeneic tumor models: Short peri‑treatment (48–96h) MERTK inhibitor dosing around cytotoxic therapy-induced tumor cell death to test whether transient blockade increases antigen presentation and improves durable ICI responses, while monitoring autoimmunity and organ efferocytosis endpoints.
2. Organ-safety panel in nonhuman primates: Evaluate retinal phagocytosis, cardiac mitochondrial health, wound healing and pulmonary efferocytosis during chronic vs intermittent MERTK inhibition at clinically relevant exposures.

Mechanistic and preclinical data give MERTK inhibition a strong biological rationale as a cancer therapy in selected contexts (overcoming therapy resistance, reprogramming TAMs). However, translational risk is nontrivial because MERTK is central to homeostatic efferocytosis in several organs; careful biomarker selection, dosing strategies, organ-safety testing, and tumor-selection are mandatory before broad clinical adoption (MERTK efferocytosis risk).

• MERTK efferocytosis study
• MERTK & EGFR resistance
• TAM in PDAC review
• MERTK in ependymoma
• Efferocytosis in cancer review